Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-12-21

Clinical Trial Update: Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating azacitidine plus amifostine in patients with myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ETHYOL (Amifostine)
  • VIDAZA (AZACITIDINE)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED